Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy.
We describe a patient with widespread and progressive cutaneous sarcoidosis who was successfully treated with anti-tumor necrosis factor-alpha monoclonal antibody, infliximab, suggesting that inhibition of tumor necrosis factor-alpha may be useful as targeted treatment in cutaneous sarcoidosis.
Mallbris
Lotus
L
Unit of Dermatology, Department of Medicine, Karolinska Institute, 171 76 Stockholm, Sweden.
Ljungberg
Anders
A
Hedblad
Mari-Anne
MA
Larsson
Per
P
Ståhle-Bäckdahl
Mona
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D005838:Genotype; D006801:Humans; D000069285:Infliximab; D008297:Male; D012507:Sarcoidosis / Q000188:drug therapy* / Q000235:genetics; D012871:Skin Diseases / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab